Acknowledgments We thank Peggy Mankin and Noorjehan Ali for their technical assistance. We also thank Shellee Abraham for manuscript preparation and Diana Meister and Sushma Jasti for manuscript review. References 1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683–2710. 2. Heimberger AB, Suki D, Yang D, Shi W, Aldape K (2005) The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3: 38. 3. Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL (2006) Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol 14: 91–96. 4. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479–489. 5. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383–1387. 6. Cancer Genome Atlas Research Network collaborators (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068. 7. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812. 8. Huang PH, Xu AM, White FM (2009) Oncogenic EGFR signaling networks in glioma. Sci Signal 2: re6. 9. Hatanpaa KJ, Burma S, Zhao D, Habib AA (2010) Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 12: 675–684. 10. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211–225. 11. Waterman H, Yarden Y (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490: 142–152. 12. Boerner JL, Demory ML, Silva C, Parsons SJ (2004) Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 24: 7059–7071. 13. Carpentier JL, Rees AR, Gregoriou M, Kris R, Schlessinger J, et al. (1986) Subcellular distribution of the external and internal domains of the EGF receptor in A-431 cells. Exp Cell Res 166: 312–326. 14. Lin SY, Makino K, Xia W, Matin A, Wen Y, et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802–808. 15. Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, et al. (2009) Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J Biol Chem 284: 36592–36604. 16. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493–507. 17. Fan QW, Weiss WA (2005) RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 24: 829–837. 18. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, et al. (2006) Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 5: 209–218. 19. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, et al. (2005) Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL2/2 renal cancer. Cancer Res 65: 5221–5230. 20. Yao Y, Wang G, Li Z, Yan B, Guo Y, et al. (2010) Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability. Acta Biochim Biophys Sin (Shanghai) 42: 763–770. 21. Dasari VR, Velpula KK, Kaur K, Fassett D, Klopfenstein JD, et al. (2010) Cord Blood Stem Cell-Mediated Induction of Apoptosis in Glioma Downregulates X- Linked Inhibitor of Apoptosis Protein (XIAP). PLoS One 5: e11813. 22. Dasari VR, Kaur K, Velpula KK, Dinh DH, Tsung AJ, et al. (2010) Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY) 2: 1–13. 23. Dasari VR, Kaur K, Velpula KK, Gujrati M, Fassett D, et al. (2010) Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One 5: e10350. 24. Velpula KK, Dasari VR, Tsung AJ, Gondi CS, Klopfenstein JD, et al. (2011) Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1. PlosOne 6: e18017. 25. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011–7021. 26. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391–403. Inhibition of EGFR Localization to Mitochondria Author Contributions Conceived and designed the experiments: VRD AJT. Performed the experiments: VRD KKV KA. Analyzed the data: VRD KKV MG AJT. Contributed reagents/materials/analysis tools: AJT. Wrote the paper: VRD. Final approval of the paper: AJT. 27. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, et al. (1998) Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 102: 1385–1392. 28. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999) ErbB receptor- induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274: 17209–17218. 29. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, et al. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274: 8335–8343. 30. Barre’ B, Vigneron A, Coqueret O (2005) The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J Biol Chem 280: 15673–15681. 31. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, et al. (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66: 2544–2552. 32. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, et al. (2001) Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 7: 517–528. 33. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, et al. (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101: 10602–10607. 34. Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903–913. 35. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127–137. 36. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, et al. (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65: 1181–1188. 37. Jones RB, Gordus A, Krall JA, MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439: 168–174. 38. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2: 203–210. 39. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6: 209–214. 40. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, et al. (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375–1382. 41. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345. 42. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966. 43. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132. 44. Bonawitz ND, Clayton DA, Shadel GS (2006) Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Mol Cell 24: 813–825. 45. Goldenthal MJ, Marin-Garcia J (2004) Mitochondrial signaling pathways: a receiver/integrator organelle. Mol Cell Biochem 262: 1–16. 46. Newmeyer DD, Ferguson-Miller S (2003) Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112: 481–490. 47. Hajnoczky G, Hoek JB (2007) Cell signaling. Mitochondrial longevity pathways. Science 315: 607–609. 48. Salvi M, Brunati AM, Toninello A (2005) Tyrosine phosphorylation in mitochondria: a new frontier in mitochondrial signaling. Free Radic Biol Med 38: 1267–1277. 49. Satrustegui J, Pardo B, Del AA (2007) Mitochondrial transporters as novel targets for intracellular calcium signaling. Physiol Rev 87: 29–67. 50. Yue X, Song W, Zhang W, Chen L, Xi Z, et al. (2008) Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival. Autophagy 4: 641–649. 51. Dasari VR, Veeravalli KK, Saving KL, Gujrati M, Klopfenstein JD, et al. (2008) Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway. Neurobiol Dis 32: 486–498. PLoS ONE | www.plosone.org 13 February 2012 | Volume 7 | Issue 2 | e31884